You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • FRI0019 Clinical Responses by Baseline RA Disease Duration in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - prognosis, predictors and outcome
FRI0019 Clinical Responses by Baseline RA Disease Duration in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Schiff M, Weinblatt M, Valente R, et al
FRI0019 Clinical Responses by Baseline RA Disease Duration in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results
Annals of the Rheumatic Diseases 2014;73:387-388.